Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigation

Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer

Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K.H. Chun and Philipp Mandel
Journal of Nuclear Medicine January 2025, 66 (1) 61-66; DOI: https://doi.org/10.2967/jnumed.124.268807
Mike Wenzel
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florestan Koll
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benedikt Hoeh
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clara Humke
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolin Siech
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolai Mader
2Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Sabet
2Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Groener
2Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Steuber
3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;
4Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Graefen
3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Maurer
3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;
4Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Brandts
5Hematology/Oncology, Department of Medicine, University Hospital Frankfurt, Goethe University, Frankfurt Am Main, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Severine Banek
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix K.H. Chun
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Mandel
1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 66 no. 1 61-66
DOI 
https://doi.org/10.2967/jnumed.124.268807
PubMed 
39542702

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 16, 2024
  • Accepted for publication October 31, 2024
  • Published online January 3, 2025.

Article Versions

  • previous version (November 14, 2024 - 06:40).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2025 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Mike Wenzel1,
  2. Florestan Koll1,
  3. Benedikt Hoeh1,
  4. Clara Humke1,
  5. Carolin Siech1,
  6. Nicolai Mader2,
  7. Amir Sabet2,
  8. Daniel Groener2,
  9. Thomas Steuber3,4,
  10. Markus Graefen3,
  11. Tobias Maurer3,4,
  12. Christian Brandts5,
  13. Severine Banek1,
  14. Felix K.H. Chun1 and
  15. Philipp Mandel1,3
  1. 1Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  2. 2Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany;
  3. 3Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;
  4. 4Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and
  5. 5Hematology/Oncology, Department of Medicine, University Hospital Frankfurt, Goethe University, Frankfurt Am Main, Germany
  1. For correspondence or reprints, contact Mike Wenzel (mike.wenzel{at}unimedizin-ffm.de).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 3 Citations
  • 4 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy
    Mike Wenzel, Benedikt Hoeh, Carolin Siech, Florestan Koll, Clara Humke, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Severine Banek, Felix K. H. Chun, Philipp Mandel
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 6
  • 177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
    Michael Froehner, Klaus Zöphel
    Journal of Nuclear Medicine 2025
  • Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients
    Mike Wenzel, Lena Theissen, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Benedikt Hoeh, Carolin Siech, Severine Banek, Felix K. H. Chun, Philipp Mandel
    European Journal of Nuclear Medicine and Molecular Imaging 2025
  • Reply to “177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?”
    Mike Wenzel, Daniel Groener, Felix K. H. Chun, Philipp Mandel
    Journal of Nuclear Medicine 2025

Article usage

Article usage: November 2024 to April 2025

AbstractFullPdf
Nov 2024253210985
Dec 20242376279135
Jan 20252124192140
Feb 20257929060
Mar 202546310688
Apr 20254004433
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 66 (1)
Journal of Nuclear Medicine
Vol. 66, Issue 1
January 1, 2025
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K.H. Chun, Philipp Mandel
Journal of Nuclear Medicine Jan 2025, 66 (1) 61-66; DOI: 10.2967/jnumed.124.268807

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Real-World Comparison of Cabazitaxel Versus 177Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts, Severine Banek, Felix K.H. Chun, Philipp Mandel
Journal of Nuclear Medicine Jan 2025, 66 (1) 61-66; DOI: 10.2967/jnumed.124.268807
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • 177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?
  • Reply to "177Lu-PSMA Radiopharmaceutical Therapy or Cabazitaxel?"
  • Google Scholar

More in this TOC Section

  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
  • Transarterial Radioembolization in the TACOME Trial: Dosimetric Analysis and Clinical Features in Predicting Response and Overall Survival
  • Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice
Show more Clinical Investigation

Similar Articles

Keywords

  • mCRPC
  • PFS
  • OS
  • survival
  • 177Lu
SNMMI

© 2025 SNMMI

Powered by HighWire